Gimopharm Sarl – FDA 483, Jul 30, 2019
This FDA Form 483 report details significant deficiencies at Ginopharm Sarl, a contract testing laboratory in Longjumeau, France, following an inspection from July 29-30, 2019. The observations highlight inadequate laboratory controls, poor record-keeping, failures within the quality control unit, and insufficient employee training, with several issues being repeat observations from a 2014 inspection. These findings indicate a lack of adherence to current good manufacturing practice regulations.
ID · ed827d83-9d60-4d7e-a84e-2596db5c701f
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.